Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A negative coregulator for the human ER.

John D Norris1, Daju Fan, Andrea Sherk

  • 1Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina 27710, USA.

Molecular Endocrinology (Baltimore, Md.)
|March 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-cell transcriptomics reveals immune landscape dynamics in metastatic hormone receptor-positive breast cancer treated with abemaciclib and endocrine therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Bert W. O'Malley (1936-2025): A great scientist, mentor, and proud Irishman.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Bert W. O'Malley (1936-2025): A great scientist, mentor, and proud Irishman.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.

Molecular cancer therapeutics·2025
Same author

Targeting androgen receptor signaling to enhance cancer immunotherapy.

Trends in pharmacological sciences·2025
Same journal

Editorial Reflections on the Demise of Molecular Endocrinology and the Future of Molecular Hormone Action Research.

Molecular endocrinology (Baltimore, Md.)·2016
Same journal

Origins of the Field of Molecular Endocrinology: A Personal Perspective.

Molecular endocrinology (Baltimore, Md.)·2016
Same journal

Bidding a Fond Farwell to Molecular Endocrinology.

Molecular endocrinology (Baltimore, Md.)·2016
Same journal

Editorial: Centennial Celebration - An Interview With Professor Evan Simpson on Hormones and Cancer.

Molecular endocrinology (Baltimore, Md.)·2016
Same journal

Editorial: Reflections on the Impact of Molecular Endocrinology on a Scientific Career.

Molecular endocrinology (Baltimore, Md.)·2016
Same journal

Reflections on the Merger of Molecular Endocrinology and Endocrinology.

Molecular endocrinology (Baltimore, Md.)·2016
See all related articles

Researchers identified a novel protein, repressor of tamoxifen transcriptional activity (RTA), that regulates estrogen receptor alpha (ERalpha) activity. RTA

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Cancer Research

Background:

  • Estrogen receptor alpha (ERalpha) is a critical transcription factor regulating cell proliferation and differentiation.
  • Aberrant ERalpha activity is implicated in diseases like breast cancer.
  • ERalpha transcriptional activity is modulated by a network of coregulatory proteins.

Purpose of the Study:

  • To identify novel coregulatory proteins of ERalpha.
  • To investigate the role of a newly isolated protein, RTA, in ERalpha transcriptional regulation.

Main Methods:

  • Isolation and characterization of the RTA protein.
  • In vitro RNA binding assays.
  • Studies on the interaction of RTA with the ERalpha N-terminal activation domain.

Related Experiment Videos

  • Analysis of RTA's effect on ERalpha activity in the presence of E2 and tamoxifen.
  • Site-directed mutagenesis of the RTA RNA recognition motif.

    • Main Results:

    • RTA, a novel protein with an RNA recognition motif, interacts with ERalpha.
    • RTA binds RNA in vitro and inhibits tamoxifen's partial agonist activity on ERalpha.
    • Mutating the RNA recognition motif yields a dominant-negative RTA, enhancing antiestrogen activity and ERalpha agonist efficacy.

    Conclusions:

    • RNA-binding proteins, like RTA, function as coregulators for nuclear receptors.
    • RTA represents a novel mechanism influencing antiestrogen activity and ERalpha signaling.
    • Findings suggest RTA's potential role in modulating therapeutic responses in ERalpha-positive cancers.